AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34313843
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 1 g
Trial: 36017782
Drug: Multiple-day dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiple-day dexamethasone (DEX) plus palonosetron and NK-1 receptor antagonists (NK-1RAs)
Trial: 35660990
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg/day
Trial: 35660990
Drug: Clonazepam 1
RxNorm normalized name: clonazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 1 mg/day
Trial: 35660990
Drug: Trazodone 50
RxNorm normalized name: traZODone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50 mg/day
Trial: 32720618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous hypoglycemic therapy)
Trial: 36145177
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg choline/d
Trial: 38386178
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg every 4 weeks (Q4W)
Trial: 33568556
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg at Week0, Week4, then Q8W
Trial: 32501276
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (improved treatment as usual - iTAU)
Trial: 33871218
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg/day for 12 weeks)
Trial: 34251458
Drug: Total FORTA
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total FORTA and potentially inappropriate medication score
Trial: 34251458
Drug: Men and
RxNorm normalized name: MINOXIDIL 2 g in 100 mL TOPICAL SOLUTION [Loesch Hair Regrowth Formula Unscented Topical Solution Regular-Strength for Men and Women]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men and rectal cancer patients
Trial: 32007513
Drug: Serlopitant 5
RxNorm normalized name: Serlopitant
DrugBank: Serlopitant (DB12973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serlopitant 5 mg daily for 8 weeks
Trial: 32553790
Drug: Combination postoperative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination postoperative radiotherapy (PORT) and androgen deprivation therapy (ADT)
Trial: 34479619
Drug: Anyu Peibo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anyu Peibo Capsule (1.6 g per day for 8 weeks)
Trial: 35819570
Drug: macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: macitentan 10 mg
Trial: 32182387
Drug: Topical ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketoconazole 2% cream twice daily and placebo (GI)
Trial: 32182387
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% adapalene gel twice daily and placebo (GII)
Trial: 32182387
Drug: Topical combination
RxNorm normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical combination of 0.1% adapalene gel (at night) and ketoconazole 2% cream (in the morning) (GIII)
Trial: 35015037
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous semaglutide, 2.4 mg
Trial: 35015037
Drug: Once-daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily subcutaneous liraglutide, 3.0 mg
Trial: 32556276
Drug: Antiparasitic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparasitic treatment (specifics not provided)
Trial: 32556276
Drug: Mild antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild antibody response
Trial: 32556276
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose albendazole regime
Trial: 32556276
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of dexamethasone
Trial: 35941584
Drug: Canagliflozin treatment
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin treatment
Trial: 34160288
Drug: 20 IU·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU·kg body wt-1 rHuEPO injections every second day for 3 weeks at sea level
Trial: 34160288
Drug: Concurrent rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent rHuEPO treatment and altitude exposure
Trial: 33210604
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (300 mg)
Trial: 33210604
Drug: Magnesium-vitamin B6
RxNorm normalized name: magnesium oxide / vitamin B6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-vitamin B6 supplementation (300 mg magnesium + 30 mg vitamin B6)
Trial: 32431667
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg/day)
Trial: 36242622
Drug: Biodegradable hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodegradable hyaluronic acid microneedle patch (BHMN patch)
Trial: 36242622
Drug: Needleless patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needleless patch (NL patch)
Trial: 36242622
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (BHMN patch and NL patch)
Trial: 34217127
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with 3% lavender oil (2.5 cc, gentle massage for 10 min every night for a month)
Trial: 36307315
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic medicines (IHMs)
Trial: 32133910
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of L-tyrosine
Trial: 32143877
Drug: Threshold inspiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold inspiratory muscle training (TIMT) at 30% of maximal inspiratory pressure (MIP) for 15 min, twice per day for 8 weeks
Trial: 39186921
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events (TEAEs)
Trial: 32437507
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks until disease progression, unacceptable toxic effects, or death
Trial: 32437507
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg every 2 weeks until disease progression, unacceptable toxic effects, or death
Trial: 33846727
Drug: Supplemental soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental soybean meal at 100% of the estimated rumen‐degradable protein requirement (F) provided daily (D)
Trial: 33846727
Drug: Supplemental soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental soybean meal at 50% of the estimated rumen‐degradable protein requirement (H) provided daily (D)
Trial: 33846727
Drug: All supplements
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All supplements provided
Trial: 32854869
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment of SCD
Trial: 32854869
Drug: Penicillin, vaccines,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin, vaccines, and hydroxyurea
Trial: 34993933
Drug: Eflapegrastim (1.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflapegrastim (1.1, 3.3, 10, 45, 135, and 270 μg/kg)
Trial: 38194162
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg)
Trial: 32756094
Drug: Pureed rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pureed rice with gelling agent
Trial: 32756094
Drug: Pureed rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pureed rice without gelling agent
Trial: 32756094
Drug: Older patients
RxNorm normalized name: black alder pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older patients (irrespective of gelling agent presence)
Trial: 35776835
Drug: Oxycodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10 mg)
Trial: 33548380
Drug: High-polyphenolic extra
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-polyphenolic extra virgin olive oil (EVOO), 50 mL
Trial: 33548380
Drug: Refined olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined olive oil without polyphenols, 50 mL
Trial: 34107792
Drug: Topical silicone
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone gel only
Trial: 616520941
Drug: PI +
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI + RTV + TVD (multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF)
Trial: 36153205
Drug: Voice treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice treatment with Acapella Choice device plus vocal hygiene program
Trial: 36153205
Drug: Voice treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice treatment with Water resistance therapy plus vocal hygiene program
Trial: 34337965
Drug: Omeprazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (1 mg/kg, PO, q 12 h)
Trial: 34337965
Drug: Famotidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (1 mg/kg, PO, q 12 h)
Trial: 37280508
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) oxygen therapy
Trial: 32423462
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion (EI) of β-lactam antibiotics (BLA)
Trial: 32423462
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion (II) of β-lactam antibiotics (BLA)
Trial: 32712762
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg kg−1 bolus followed by 10 mcg kg−1 min−1 infusion
Trial: 32712762
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg kg−1 bolus followed by 5 mcg kg−1 min−1 infusion
Trial: 32702911
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with electroacupuncture (EA) and computerized cognitive rehabilitation treatment (CCRT)
Trial: 32702911
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with transcranial direct current stimulation (tDCS) and computerized cognitive rehabilitation treatment (CCRT)
Trial: 32702911
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive rehabilitation treatment (CCRT) alone
Trial: 32702911
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with EA and CCRT
Trial: 32702911
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with tDCS and CCRT
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels ≤16 ng/mL for GDM
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels 16–26 ng/mL for GDM
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels >26 ng/mL for GDM
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels ≤15 ng/mL for preterm delivery
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels 15–21 ng/mL for preterm delivery
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels >21 ng/mL for preterm delivery
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels ≤15 ng/mL for preeclampsia
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels 15–23 ng/mL for preeclampsia
Trial: 33039154
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels >23 ng/mL for preeclampsia
Trial: 35994896
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone therapy (MHT) containing 1 or 2 mg of estradiol and cyclical 10 mg dydrogesterone for one year
Trial: 36124667
Drug: Weekly exercise
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly exercise
Trial: 32823594
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg·kg−1·body mass)
Trial: 33861384
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavioral therapy (CBT) for OCD, 14 weekly sessions
Trial: 32354152
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g PHGG up to three times per day for 3 weeks
Trial: 34420375
Drug: Venlafaxine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (1 mg/kg for 60 days)
Trial: 34851411
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg per day intranasal OP0201 for 10 days
Trial: 34426106
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg, subcutaneous, once)
Trial: 34914294
Drug: Yishen Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishen Huoxue Decoction (1 dose a day, twice daily for 3 months)
Trial: 34914294
Drug: Shengjing Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengjing Tablets (4 tablets once, tid) combined with L-carnitine oral solution (10 ml, bid for 3 months)
Trial: 32787925
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed therapy (DOT)
Trial: 33662951
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic medicines (IH) plus psychological counseling (PC)
Trial: 32768154
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS with 3 mA and low dosage of flunarizine (2.5 mg)
Trial: 32768154
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS with 3 mA and medium dosage of flunarizine (5 mg)
Trial: 32768154
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS with 3 mA and high dosage of flunarizine (10 mg)
Trial: 34187460
Drug: Guided self-study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-study (G‐SS)
Trial: 34954406
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil therapy
Trial: 34967899
Drug: Bupivacaine liposome
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine liposome suspension block + oral placebo (BUP)
Trial: 34967899
Drug: Lidocaine block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine block + oral placebo (LID)
Trial: 34967899
Drug: Lidocaine block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine block + oral meloxicam (1 mg/kg) (LID + MEL)
Trial: 34967899
Drug: Saline block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline block + oral placebo (CON)
Trial: 35992984
Drug: Platelet Rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet Rich Plasma Injection (Group I)
Trial: 34228393
Drug: Oral‐B 3D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B 3D White Luxe/Procter & Gamble (WL)
Trial: 32933348
Drug: Compassion-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassion-focused therapy (CFT) - 8 sessions
Trial: 33878858
Drug: Pulse-steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-steroid treatment (250 mg/day methyl-prednisolone)
Trial: 33878858
Drug: High-dose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroid treatment (6 mg/day dexamethasone equivalent)
Trial: 33878858
Drug: Standard-care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care therapy alone
Trial: 38124551
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel
Trial: 32875492
Drug: Double VEGF/HGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double VEGF/HGF gene therapy
Trial: 36428274
Drug: Sham Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Therapy (ST)
Trial: 36349758
Drug: S‐methyl‐L‐thiocitrulline (nNOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐methyl‐L‐thiocitrulline (nNOS inhibitor)
Trial: 33789252
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received no intervention, only routine treatment.
Trial: 32326719
Drug: Daily outdoor
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily outdoor time for more than 1 hour
Trial: 35465297
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 (mGSTP1)
Trial: 35465297
Drug: Continue docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continue docetaxel 75 mg/m2 q3w in accordance with clinician’s usual practice
Trial: 33853721
Drug: shamTMS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: shamTMS group (sham treatment)
Trial: 35028668
Drug: Lenacapavir (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenacapavir (up to 750 mg, single dose)
Trial: 35028668
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 day monotherapy)
Trial: 36031718
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg ethanol
Trial: 38286618
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg)
Trial: 33726843
Drug: Electronic prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic prompt embedded in a Clinical Decision Support System (CDSS) for Screening, Brief intervention, and Referral to Treatment (SBIRT)
Trial: 36348476
Drug: 0.15 g/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 g/Kg C-IVIG with standard of care (SOC)
Trial: 32725073
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid therapy
Trial: 35959833
Drug: Changing nasogastric
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing nasogastric feeding tubes daily during the first week of life
Trial: 35959833
Drug: Changing nasogastric
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing nasogastric feeding tubes weekly (on day seven)